Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

43 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Divergent WNT signaling and drug sensitivity profiles within hepatoblastoma tumors and organoids.
Kluiver TA, Lu Y, Schubert SA, Kraaier LJ, Ringnalda F, Lijnzaad P, DeMartino J, Megchelenbrink WL, Amo-Addae V, Eising S, de Faria FW, Münter D, van de Wetering M, Kerl K, Duiker E, van den Heuvel MC, de Meijer VE, de Kleine RH, Molenaar JJ, Margaritis T, Stunnenberg HG, de Krijger RR, Zsiros J, Clevers H, Peng WC. Kluiver TA, et al. Among authors: eising s. Nat Commun. 2024 Nov 20;15(1):8576. doi: 10.1038/s41467-024-52757-w. Nat Commun. 2024. PMID: 39567475 Free PMC article.
The potential of PARP as a therapeutic target across pediatric solid malignancies.
Keller KM, Koetsier J, Schild L, Amo-Addae V, Eising S, van den Handel K, Ober K, Koopmans B, Essing A, van den Boogaard ML, Langenberg KPS, Jäger N, Kool M, Pfister S, Dolman MEM, Molenaar JJ, van Hooff SR. Keller KM, et al. Among authors: eising s. BMC Cancer. 2023 Apr 5;23(1):310. doi: 10.1186/s12885-022-10319-7. BMC Cancer. 2023. PMID: 37020198 Free PMC article.
MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastoma.
Eleveld TF, Vernooij L, Schild L, Koopmans B, Alles LK, Ebus ME, Dandis R, van Tinteren H, Caron HN, Koster J, van Noesel MM, Tytgat GAM, Eising S, Versteeg R, Dolman MEM, Molenaar JJ. Eleveld TF, et al. Among authors: eising s. Front Oncol. 2023 Feb 21;13:1130034. doi: 10.3389/fonc.2023.1130034. eCollection 2023. Front Oncol. 2023. PMID: 36895472 Free PMC article.
Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma.
Keller KM, Eleveld TF, Schild L, van den Handel K, van den Boogaard M, Amo-Addae V, Eising S, Ober K, Koopmans B, Looijenga L, Tytgat GAM, Ylstra B, Molenaar JJ, Dolman MEM, van Hooff SR. Keller KM, et al. Among authors: eising s. Front Oncol. 2022 Sep 27;12:929123. doi: 10.3389/fonc.2022.929123. eCollection 2022. Front Oncol. 2022. PMID: 36237330 Free PMC article.
Mesenchymal tumor organoid models recapitulate rhabdomyosarcoma subtypes.
Meister MT, Groot Koerkamp MJA, de Souza T, Breunis WB, Frazer-Mendelewska E, Brok M, DeMartino J, Manders F, Calandrini C, Kerstens HHD, Janse A, Dolman MEM, Eising S, Langenberg KPS, van Tuil M, Knops RRG, van Scheltinga ST, Hiemcke-Jiwa LS, Flucke U, Merks JHM, van Noesel MM, Tops BBJ, Hehir-Kwa JY, Kemmeren P, Molenaar JJ, van de Wetering M, van Boxtel R, Drost J, Holstege FCP. Meister MT, et al. Among authors: eising s. EMBO Mol Med. 2022 Oct 10;14(10):e16001. doi: 10.15252/emmm.202216001. Epub 2022 Aug 2. EMBO Mol Med. 2022. PMID: 35916583 Free PMC article.
Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells.
Berlak M, Tucker E, Dorel M, Winkler A, McGearey A, Rodriguez-Fos E, da Costa BM, Barker K, Fyle E, Calton E, Eising S, Ober K, Hughes D, Koutroumanidou E, Carter P, Stankunaite R, Proszek P, Jain N, Rosswog C, Dorado-Garcia H, Molenaar JJ, Hubank M, Barone G, Anderson J, Lang P, Deubzer HE, Künkele A, Fischer M, Eggert A, Kloft C, Henssen AG, Boettcher M, Hertwig F, Blüthgen N, Chesler L, Schulte JH. Berlak M, et al. Among authors: eising s. Mol Cancer. 2022 Jun 10;21(1):126. doi: 10.1186/s12943-022-01583-z. Mol Cancer. 2022. PMID: 35689207 Free PMC article.
43 results